DOV KADMON to Prodrugs
This is a "connection" page, showing publications DOV KADMON has written about Prodrugs.
Connection Strength
0.037
-
Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):562-71.
Score: 0.013
-
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9.
Score: 0.013
-
Gene therapy for prostate cancer. Expert Rev Anticancer Ther. 2002 Jun; 2(3):309-21.
Score: 0.011